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Background
The fourth wave of the opioid epidemic is described as fentanyl 
PLUS many other substances, including designer benzodiazepines 
such as clonazolam, which is an analogue of clonazepam  
and a potent GABAA agonist. Co-exposure of designer 
benzodiazepines with illicit opioids may confound antidotal 
treatment, delay therapeutic response, and in the long term, 
lead to addiction and withdrawal. We report a regional 
clonazolam outbreak in ED patients with illicit opioid overdose.
Methods 
This is a case series from the Toxicology Investigators Consortium 
(ToxIC) Fentalog study group, an ongoing cohort study at nine 
sites located across the United States. Consecutive adult  
ED patients from 5 participating facilities who presented 
following a suspected acute opioid overdose were screened  
for enrollment, which included comprehensive toxicological 
testing. Waste clinical specimens were analyzed via liquid 
chromatography quadrupole time-of-flight mass spectrometry 
for the presence of over 900 psychoactive substances and 
their metabolites. Cases with clonazolam identified in biologic 
samples were included in this series, and medical records 
review was performed. 
Results
In patients evaluated between 10/6/20–3/9/21, out of 141 
samples taken from presumed opioid overdoses from 5 clinical 
sites encompassing 4 states (Missouri, Oregon, New York, and 
Pennsylvania), 11 blood samples detected the presence of 
clonazolam. Of these 11 patients, 8 (72.7%) were positive in 
Pennsylvania, 2 (18.2%) in Missouri, and 1 (9.1%) in Oregon. All 
ranged between ages 18-65 (mean age = 37) and the majority 
occurred in men (N = 8, 72.7%). Age, sex and geographic 
location are reported in Table 1. Current sedative/hypnotic use 
(use < 30 days prior) was reported in 1 (9.1%) and unknown use 
history in the other 10 (90.9%). Confirmed opioid analytes 
found in clinical specimens are listed in Table 1. Naloxone was 
given in 9 (81.8%) and the response after treatment with the 
first dose was known in 7 of these cases. Out of these 7 
patients, no response with first dose was noted in 4 (57.1%), 
and improved level of consciousness was noted in 2 (28.6%). 
There were no deaths.
Conclusion 
This case series confirms an ongoing clonazolam outbreak. 
Clinicians should recognize that illicit opioid overdoses may  




AGE SEX* LOCATION OPIOID ANALYTES DETECTED
31 M Pennsylvania Methadone
47 F Pennsylvania Methadone
39 F Pennsylvania None
42 M Pennsylvania Methadone, Trazodone
57 M Pennsylvania Methadone
27 M Pennsylvania Methadone, Heroin, Para-Fluorofentanyl, Acetyl Fentanyl
37 M Oregon Heroin, Codeine
32 F Pennsylvania Methadone
35 M Pennsylvania Fentanyl
27 M Missouri Fentanyl, Para-Fluorofentanyl
36 M Missouri Brorphine, Fentanyl
*M = male, F = female
clonazolam detected in
11 of 141 
blood samples
